EPHA3 and plasma cell myeloma: Moreover, EPHA3 is a viable anti-leukaemic target, with the success of an activating monoclonal antibody (IIIA4), targeted payload delivery, or RNAi-mediated EPHA3 knockdown in models of multiple myeloma [26] and pre-B-ALL [27], as well as in human myeloid malignancies [28].